Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Oncorus stock | $9.83

Learn how to easily invest in Oncorus stock.

Oncorus Inc
NASDAQ: ONCR - USD
BIOTECHNOLOGY
$10.53
+ $0.70 ( + 7.12%)

Oncorus Inc is a biotechnology business based in the US. Oncorus shares (ONCR) are listed on the NASDAQ and all prices are listed in US Dollars. Oncorus employs 56 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Oncorus

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONCR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Oncorus stock price (NASDAQ: ONCR)

Use our graph to track the performance of ONCR stocks over time.

Oncorus shares at a glance

Information last updated 2021-10-16.
Latest market close$9.83
52-week range$8.75 - $37.86
50-day moving average $9.68
200-day moving average $13.08
Wall St. target price$37.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.46

Buy Oncorus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oncorus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oncorus price performance over time

Historical closes compared with the close of $9.83 from 2021-10-20

1 week (2021-10-14) 2.29%
1 month (2021-09-22) 3.04%
3 months (2021-07-22) -25.87%
6 months (2021-04-22) -31.93%
1 year (2020-10-21) -34.47%
2 years (2019-10-18) N/A
3 years (2018-10-18) N/A
5 years (2016-10-18) N/A

Oncorus financials

Gross profit TTM $0
Return on assets TTM -24.2%
Return on equity TTM -62.94%
Profit margin 0%
Book value $6.32
Market capitalisation $246.9 million

TTM: trailing 12 months

Shorting Oncorus shares

There are currently 687,961 Oncorus shares held short by investors – that's known as Oncorus's "short interest". This figure is 2.5% up from 671,076 last month.

There are a few different ways that this level of interest in shorting Oncorus shares can be evaluated.

Oncorus's "short interest ratio" (SIR)

Oncorus's "short interest ratio" (SIR) is the quantity of Oncorus shares currently shorted divided by the average quantity of Oncorus shares traded daily (recently around 90640.447957839). Oncorus's SIR currently stands at 7.59. In other words for every 100,000 Oncorus shares traded daily on the market, roughly 7590 shares are currently held short.

To gain some more context, you can compare Oncorus's short interest ratio against those of similar companies.

However Oncorus's short interest can also be evaluated against the total number of Oncorus shares, or, against the total number of tradable Oncorus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncorus's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Oncorus shares in existence, roughly 30 shares are currently held short) or 0.0638% of the tradable shares (for every 100,000 tradable Oncorus shares, roughly 64 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Oncorus.

Find out more about how you can short Oncorus stock.

Oncorus share dividends

We're not expecting Oncorus to pay a dividend over the next 12 months.

Oncorus overview

Oncorus, Inc. , a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

What percentage of Oncorus is owned by insiders or institutions?
Currently 2.397% of Oncorus shares are held by insiders and 79.355% by institutions.
How many people work for Oncorus?
Latest data suggests 56 work at Oncorus.
When does the fiscal year end for Oncorus?
Oncorus's fiscal year ends in December.
Where is Oncorus based?
Oncorus's address is: 50 Hampshire Street, Cambridge, MA, United States, 02139
What is Oncorus's ISIN number?
Oncorus's international securities identification number is: US68236R1032

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site